Appili Therapeutics Inc.
APLIF
$0.01
$0.00-1.27%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 18.20K | 82.50K | 75.50K | -- | -8.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.20K | 82.50K | 75.50K | -- | -8.80K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 18.20K | 82.50K | 75.50K | -- | -8.80K |
| SG&A Expenses | 715.00K | 184.30K | 413.70K | 464.40K | 692.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.10M | 597.00K | 1.02M | 1.16M | 1.76M |
| Operating Income | -2.08M | -514.50K | -942.90K | -1.16M | -1.77M |
| Income Before Tax | -724.90K | -674.00K | -692.70K | -880.90K | 178.20K |
| Income Tax Expenses | 29.50K | 7.00K | 25.40K | 22.30K | 19.30K |
| Earnings from Continuing Operations | -754.40K | -681.10K | -718.10K | -903.20K | 158.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -754.40K | -681.10K | -718.10K | -903.20K | 158.90K |
| EBIT | -2.08M | -514.50K | -942.90K | -1.16M | -1.77M |
| EBITDA | -2.08M | -512.90K | -940.50K | -1.16M | -1.76M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 109.78M | 128.37M | 121.27M | 121.27M | 121.27M |
| Average Diluted Shares Outstanding | 109.78M | 128.37M | 121.27M | 121.27M | 121.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |